S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
The Largest Ever Technology Wave Is Coming! (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
Is Graphite the New Lithium? (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Is Graphite the New Lithium? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
The Largest Ever Technology Wave Is Coming! (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
Is Graphite the New Lithium? (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Is Graphite the New Lithium? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
The Largest Ever Technology Wave Is Coming! (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
Is Graphite the New Lithium? (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Is Graphite the New Lithium? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
The Largest Ever Technology Wave Is Coming! (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
Is Graphite the New Lithium? (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Is Graphite the New Lithium? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
NASDAQ:GBT

Global Blood Therapeutics (GBT) Price Target & Analyst Ratings

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$68.49
▼
$68.49
50-Day Range
$68.07
▼
$68.49
52-Week Range
$21.65
▼
$73.02
Volume
74 shs
Average Volume
2.07 million shs
Market Capitalization
$4.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.44
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Global Blood Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 12 Analyst Ratings

Consensus Analyst Price Target

$66.44
-3.00% Downside
High Prediction$74.00
Average Prediction$66.44
Low Prediction$36.00
TypeCurrent
5/30/22 to 5/30/23		1 Month Ago
4/30/22 to 4/30/23		3 Months Ago
3/1/22 to 3/1/23		1 Year Ago
5/30/21 to 5/30/22
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
9 Buy rating(s)
Hold
10 Hold rating(s)
10 Hold rating(s)
10 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$66.44$66.94$67.75$57.27
Predicted Upside-3.00% Downside19.66% Upside24.61% Upside88.81% Upside
Get Global Blood Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.


GBT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GBT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Global Blood Therapeutics Stock vs. The Competition

TypeGlobal Blood TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.17
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside-3.00% Downside1,325.55% Upside197.55% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/21/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		L. Watsek
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingNeutral
8/15/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$72.00+7.40%
8/15/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating		A. Argyrides
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeNeutral
8/15/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeHold
8/15/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeMarket Perform
8/9/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform$68.50+2.90%
8/9/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOverweight ➝ Equal Weight$66.00 ➝ $68.50+2.85%
8/9/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeMarket Perform$67.00 ➝ $68.50+2.85%
8/8/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Hold
8/8/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating		R. Prasad
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform
8/8/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		John Newman
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeHold ➝ Buy$40.00 ➝ $72.00+12.78%
6/28/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral$39.00 ➝ $36.00+21.01%
(Data available from 5/30/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












GBT Price Target - Frequently Asked Questions

What is Global Blood Therapeutics's consensus rating and price target?

According to the issued ratings of 12 analysts in the last year, the consensus rating for Global Blood Therapeutics stock is Hold based on the current 10 hold ratings and 2 buy ratings for GBT. The average twelve-month price prediction for Global Blood Therapeutics is $66.44 with a high price target of $74.00 and a low price target of $36.00. Learn more on GBT's analyst rating history.

Do Wall Street analysts like Global Blood Therapeutics more than its competitors?

Analysts like Global Blood Therapeutics less than other Medical companies. The consensus rating for Global Blood Therapeutics is Hold while the average consensus rating for medical companies is Buy. Learn more on how GBT compares to other companies.

Does Global Blood Therapeutics's stock price have much upside?

According to analysts, Global Blood Therapeutics's stock has a predicted upside of 15.10% based on their 12-month price targets.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:GBT) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -